Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...

Avista Therapeutics Expands AI Gene Therapy Platform to Break Barriers in the Delivery of Genetic Medicines

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.
BioTechniques

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV

High-quality HIV antigens for cutting-edge solutions. On February 18, 2025, Gilead Sciences (CA, US) announced a significant milestone: the US FDA accepted their New Drug Applications (NDAs) for ...
Business Wire

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee ...